Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Effectiveness of AA4500 (Xiaflex) in Men With Peyronie's Disease
NCT01243411Phase 3Completed
- Sponsor
- Endo International plc
- Start
- Nov 2010
- Primary completion
- Aug 2012
- Modality
- Therapeutic Enzymes
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of collagenase clostridium histolyticum in Peyronie's disease, sponsored by Endo International plc. Primary endpoints: Percentage Change From Baseline in Penile Curvature at Week 36 and Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ) at Week 36. Started Nov 2010; status: completed.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
Peyronie's disease
Beyond the preview
Go deeper on NCT01243411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01243411.